{"doi":"10.1002/oby.22978","title":"A Randomized Controlled Trial of Ovarian Suppression in Premenopausal Women: No Change in Free‐Living Energy Expenditure","abstract":"Objective The purpose of this study was to determine whether suppression of ovarian function (gonadotropin‐releasing hormone agonist [GnRH AG ]) for 24 weeks in premenopausal women approaching menopause causes changes in body composition and a decline in free‐living physical activity energy expenditure (PAEE) and whether endurance exercise training attenuates the changes. Methods Premenopausal women who were approaching menopause (mean [SD]: age 46 [3] years, BMI 26.3 [4.8] kg/m 2 ) were randomized to 24 weeks of GnRH AG ( n = 14), GnRH AG + Exercise ( n = 11), or placebo ( n = 9). Endurance exercise was performed 4 days per week with the goal of expending 200 to 300 kcal per session. Primary outcome measurements included body composition by dual‐energy x‐ray absorptiometry, total daily energy expenditure (TDEE), and PAEE by doubly labeled water, and resting energy expenditure (REE) by indirect calorimetry. Results Changes in TDEE, PAEE, REE, or body composition were not different between groups. However, within the GnRH AG group, fat mass increased (mean [SE]: total 1.7 [0.4] kg, trunk 0.9 [0.2] kg, leg 0.6 [0.2] kg) and fat‐free leg mass decreased (mean [SE]: −0.4 [0.2] kg) significantly. Conclusions In premenopausal women approaching menopause, ovarian hormone suppression resulted in increased adiposity without alterations in TDEE, PAEE, or REE.","journal":"Obesity","year":2020,"id":85065,"datarank":0.39587107340231387,"base_score":2.1972245773362196,"endowment":2.1972245773362196,"self_citation_contribution":0.32958368660043297,"citation_network_contribution":0.06628738680188091,"self_endowment_contribution":0.32958368660043297,"citer_contribution":0.06628738680188091,"corpus_percentile":null,"corpus_rank":null,"citation_count":8,"citer_count":7,"citers_with_citation_signal":4,"citers_with_endowment":4,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9535,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT01712230"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":235339,"name":"Edward L. Melanson","orcid":"0000-0001-9151-9745","position":1,"is_corresponding":false},{"id":267870,"name":"Kerry L. Hildreth","orcid":"0000-0001-7463-7811","position":2,"is_corresponding":false},{"id":436796,"name":"Ellie Gibbons","orcid":null,"position":3,"is_corresponding":false},{"id":263221,"name":"Daniel H. Bessesen","orcid":"0000-0002-8242-9198","position":4,"is_corresponding":false},{"id":238664,"name":"Wendy M. Kohrt","orcid":null,"position":5,"is_corresponding":false},{"id":263220,"name":"Kathleen M. Gavin","orcid":"0000-0003-4102-8424","position":0,"is_corresponding":true}],"reference_count":40,"raw_metadata":null,"created_at":"2026-07-18T21:56:02.794896Z","pmid":"33150745","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}